Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005

American Journal of Hematology

Volumn 88, Issue 1, 2013, Pages 60-65

  Kristinsson, Sigurdur Y ^a,b,c   Eloranta, Sandra ^d   Dickman, Paul W ^d   Andersson, Therese M L ^d   Turesson, Ingemar ^e   Landgren, Ola ^a,f   Björkholm, Magnus ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ICELAND   (Iceland)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d KAROLINSKA INSTITUTE   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CONFIDENCE INTERVAL; EXCESS MORTALITY RATE RATIO; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RELATIVE SURVIVAL RATIO; STATISTICAL PARAMETERS; SWEDEN; TREATMENT RESPONSE; TREND STUDY; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; SWEDEN; TIME FACTORS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84871448748     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23351     Document Type: Article

References (38)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2008.
2. Kristinsson SY, Bjorkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: A population-based study in Sweden. Blood 2008; 112: 3052-3056.
3. Waldenström J. Incipient myelomatosis or 'essential' hyperglobulinemia with fibrinogenopenia: A new syndrome? Acta Med Scand 1944; 117: 216-247.
4. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009; 113: 4163-4170.
5. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2009; 27: 120-126.
6. Treon SP. How I treat Waldenstrom macroglobulinemia. Blood 2009; 114: 2375-2385.
7. Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenstrom's macroglobulinemia: A report of 167 cases. J Clin Oncol 1993; 11: 1553-1558.
8. Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenström macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000; 96: 852-858.
9. Merlini G, Baldini L, Broglia C, et al. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 211-215.
10. Garcia-Sanz R, Montoto S, Torrequebrada A, et al. Waldenstrom macroglobulinaemia: Presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115: 575-582.
11. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: An update of a US intergroup trial (SW0G S9003). Semin Oncol 2003; 30: 220-225.
12. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenstrom's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol 2000; 18: 214-226.
13. Gobbi PG, Bettini R, Montecucco C, et al. Study of prognosis in Waldenstrom's macroglobulinemia: A proposal for a simple binary classification with clinical and investigational utility. Blood 1994; 83: 2939-2945.
14. Bjorkholm M, Johansson E, Papamichael D, et al. Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: A two-institution study. Semin Oncol 2003; 30: 226-230.
15. Kastritis E, Kyrtsonis MC, Hatjiharissi E, et al. No significant improvement in the outcome of patients with Waldenstrom's macroglobulinemia treated over the last 25 years. Am J Hematol 2011; 86: 479-483.
16. Kristinsson SY, Koshiol J, Bjorkholm M, et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst 2010; 102: 557-567.
17. Turesson I, Linet MS, Bjorkholm M, et al. Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer 2007; 121: 2260-2266.
18. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med 2006; 260: 103-117.
19. Dimopoulos MA, Alexanian R. Waldenstrom's macroglobulinemia. Blood 1994; 83: 1452-1459.
20. Foran JM, Rohatiner AZ, Coiffier B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999; 17: 546-553.
21. Liu ES, Burian C, Miller WE, et al. Bolus administration of cladribine in the treatment of Waldenstrom macroglobulinaemia. Br J Haematol 1998; 103: 690-695.
22. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002; 20: 2327-2333.
23. Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005; 5: 273-277.
24. Treon SP, Branagan AR, Ioakimidis L, et al. Long term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2009; 113: 3673-3678.
25. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005; 90: 1655-1658.
26. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1570-1575.
27. Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenstrom's macroglobulinemia with thalidomide. J Clin Oncol 2001; 19: 3596-3601.
28. Treon SP, Hatjiharissi E, Leleu X, et al. Novel agents in the treatment of Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2007; 7(suppl 5): S199-S206.
29. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG Trial 03-248. Clin Cancer Res 2007; 13: 3320-3325.
30. Gilleece MH, Pearce R, Linch DC, et al. The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: A British Society Bone Marrow Transplantation study. Hematology 2008; 13: 119-127.
31. Anagnostopoulos A, Hari PN, Perez WS, et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 2006; 12: 845-854.
32. Kyriakou C, Canals C, Cornelissen JJ, et al. Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: Report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 4926-4934.
33. Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 2227-2232.
34. Garnier A, Robin M, Larosa F, et al. Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Haematologica 2010; 95: 950-955.
35. Hensel M, Brust J, Ploger C, et al. Excellent long-term survival of 170 patients with Waldenstrom's macroglobulinemia treated in private oncology practices and a university hospital. Ann Hematol 2012 [Epub ahead of print].
36. Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: A population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007; 25: 1993-1999.
37. Schop RF, Kuehl WM, Van Wier SA, et al. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002; 100: 2996-3001.
38. Kristinsson SY, Dickman PW, Wilson WH, et al. Improved survival in chronic lymphocytic leukemia in the past decade: A population-based study including 11, 179 patients diagnosed between 1973-2003 in Sweden. Haematologica 2009; 94: 1259-1265.